Biomarkers of abdominal aortic aneurysm progression. Part 2: Inflammation

Nature Reviews Cardiology

Volumn 6, Issue 8, 2009, Pages 543-552

  Hellenthal, Femke A M V I ^a   Buurman, Willem A ^a   Wodzig, Will K W H ^a   Schurink, Geert Willem H ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ABDOMINAL AORTA ANEURYSM; ARTICLE; BLOOD; DISEASE COURSE; HUMAN; INFLAMMATION; METABOLISM;

AORTIC ANEURYSM, ABDOMINAL; BIOLOGICAL MARKERS; DISEASE PROGRESSION; HUMANS; INFLAMMATION;

EID: 70350435948     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2009.102     Document Type: Article

References (86)

1. van der Vliet, J. A. & Boll, A. Abdominal aortic aneurysm. Lancet 349, 863-866 (1997).
2. sakalihasan, N., Limet, R. & Defawe, O. D. Abdominal aortic aneurysm. Lancet 365, 1577-1589 (2005).
3. sakalihasan, N., Limet, R. & Defawe, O. D. [No authors listed] Mortality results for randomised controlled trial of early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms. The UK Small Aneurysm Trial Participants. Lancet 352, 1649-1655 (1998).
4. Hellenthal, F. A., Geenen, I. L., Teijink, J. A., Heeneman, S. & Schurink, G. W. Histological features of human abdominal aortic aneurysm are not related to clinical characteristics. Cardiovasc. Pathol. doi:10.1016/j.carpath.2008.06.014.
5. Hellenthal, F. A., Buurman, W. A., Wodzig, W. K. & Schurink, G. Biomarkers of AAA progression. Part 1: extracellular matrix degeneration. Nat. Rev. Cardiol. doi:10.1038/nrcardio.2009.80
6. Juvonen, J. et al. Elevated circulating levels of inflammatory cytokines in patients with abdominal aortic aneurysm. Arterioscler. Thromb. Vasc. Biol. 17, 2843-2847 (1997).
7. Newman, K. M., Jean-Claude, J., Li, H., Ramey, W. G. & Tilson, M. D. Cytokines that activate proteolysis are increased in abdominal aortic aneurysms. Circulation 90, M224-M227 (1994).
8. Shimizu, K., Libby, P. & Mitchell, R. N. Local cytokine environments drive aneurysm formation in allografted aortas. Trends Cardiovasc. Med. 15, 142-148 (2005).
9. Freestone, T. et al. inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm. Arterioscler. Thromb. Vasc. Biol. 15, 1145-1151 (1995).
10. Schönbeck, U., Sukhova, G. K., Gerdes, N. & Libby, P. TH2 predominant immune responses prevail in human abdominal aortic aneurysm. Am. J. Pathol. 161, 499-506 (2002).
11. Shimizu, K., Mitchell, R. N. & Libby, P inflammation and cellular immune responses in abdominal aortic aneurysms. Arterioscler. Thromb. Vasc. Biol. 26, 987-994 (2006).
12. Parks, W. C., Wilson, C. L. & Lopez-Boado, Y S. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat. Rev. Immunol. 4, 617-629 (2004).
13. Pearce, W. H. & Koch, A. E. Cellular components and features of immune response in abdominal aortic aneurysms. Ann. NY Acad. Sci. 800, 175-185 (1996).
14. Folkesson, M. et al. Presence of NGAL/MMP-9 complexes in human abdominal aortic aneurysms. Thromb. Haemost. 98, 427-33 (2007).
15. Okusawa, S., Gelfand, J. A., ikejima, T., Connolly, R. J. & Dinarello, C. A. interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J. Clin. Invest. 81, 1162-1172 (1988).
16. Tomosugi, N. i. et al. Modulation of antibody- mediated glomerular injury in vivo by bacterial lipopolysaccharide, tumor necrosis factor, and iL-1. J. Immunol. 142, 3083-3090 (1989).
17. Hiraga, S. et al. Modulation of collagen synthesis by tumor necrosis factor a in cultured vascular smooth muscle cells. Life Sci. 66, 235-244 (2000).
18. Treska, V., Topolcan, O. & Pecen, L. Cytokines as plasma markers of abdominal aortic aneurysm. Clin. Chem. Lab. Med. 38, 1161-1164 (2000).
19. Rohde, L. E. et al. Plasma concentrations of interleukin-6 and abdominal aortic diameter among subjects without aortic dilatation. Arterioscler. Thromb. Vasc. Biol. 19, 1695-1699.
20. Pearce, W. H., Sweis, I., Yao, J. S., McCarthy, W. J. & Koch, A. E. interleukin-1ß and tumor necrosis factor-a release in normal and diseased human infrarenal aortas. J. Vasc. Surg. 16, 784-789 (1992).
21. Shi, G. P et al. Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J. Clin. Invest. 104, 1191-1197 (1999).
22. Gambarin, F. I. et al. Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation. Marfan syndrome with FBN1 gene mutations.
23. J. Cardiovasc. Med. (Hagerstown) 10, 354-362 (2009).
24. Lindholt, J. S., Jorgensen, B., Shi, G. P & Henneberg, E. W. Relationships between activators and inhibitors of plasminogen, and the progression of small abdominal aortic aneurysms. Eur. J. Vasc. Endovasc. Surg. 25, 546-551 (2003).
25. Flondell-Sité, D., Lindblad, B., Kölbel, T. & Gottsäter, A. Cytokines and systemic biomarkers are related to the size of abdominal aortic aneurysms. Cytokine 46, 211-215 (2009).
26. Bloom, B. R. & Bennett, B. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 153, 80-82 (1966).
27. Calandra, T., Bernhagen, J., Mitchell, R. A. & Bucala, R. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J. Exp. Med. 179, 1895-1902 (1994).
28. Bacher, M. et al. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc. Natl Acad. Sci. USA 93, 7849-7854 (1996).
29. Takahashi, N. et al. involvement of macrophage migration inhibitory factor (MiF) in the mechanism of tumor cell growth. Mol. Med. 4, 707-714 (1998).
30. Chesney, J. et al. An essential role for macrophage migration inhibitory factor (MiF) in angiogenesis and the growth of a murine lymphoma. Mol. Med. 5, 181-191 (1999).
31. Onodera, S. et al. Macrophage migration inhibitory factor up-regulates expression of matrix metalloproteinases in synovial fibroblasts of rheumatoid arthritis. J. Biol. Chem. 275, 444-450 (2000).
32. Meyer-Siegler, K. Macrophage migration inhibitory factor increases MMP-2 activity in DU-145 prostate cells. Cytokine 12, 914-921.
33. Pan, J. H. et al. Macrophage migration inhibitory factor is associated with aneurysmal expansion. J. Vasc. Surg. 37, 628-635 (2003).
34. Jono, S. et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 106, 1192-1194 (2002).
35. Kiechl, S. et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 109, 2175-2180 (2004).
36. Zhang, J. et al. PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways. FEBS Lett. 521, 180-184 (2002).
37. Daugherty, A. & Cassis, L. Angiotensin ii- mediated development of vascular diseases. Trends Cardiovasc. Med. 14, 117-120 (2004).
38. Nishimoto, M. et al. increased local angiotensin ii formation in aneurysmal aorta. Life Sci. 71, 2195-2205 (2002).
39. Deng, G. G. et al. Urokinase-type plasminogen activator plays a critical role in angiotensin ii- induced abdominal aortic aneurysm. Circ. Res. 92, 510-517 (2003).
40. Moran, C. S. et al. Association of osteoprotegerin with human abdominal aortic aneurysm progression. Circulation 111, 3119-3125 (2005).
41. Zuegg, J., Webb, D. C., Foster, P. S. & Casarotto, M. G. Structural model of human iL-13 defines the spatial interactions with the iL-13Ra/iL-4Ra receptor. Immunol. Cell Biol. 79, 332-339 (2001).
42. Jordan, N. J. et al. Chemokine production by human vascular smooth muscle cells: modulation by iL-13. Br. J. Pharmacol. 122, 749-757 (1997).
43. Brown, M. A. & Hural, J. Functions of iL-4 and control of its expression. Crit. Rev. Immunol. 17, 1-32 (1997).
44. Soong, C. V. et al. Bowel ischaemia and organ impairment in elective abdominal aortic aneurysm repair. Br. J. Surg. 81, 965-968 (1994).
45. Sun, J. et al. Mast cells modulate the pathogenesis of elastase-induced abdominal aortic aneurysms in mice. J. Clin. Invest. 117, 3359-3368 (2007).
46. Walton, L. J. et al. inhibition of prostaglandin E2 synthesis in abdominal aortic aneurysms: implications for smooth muscle cell viability, inflammatory processes, and the expansion of abdominal aortic aneurysms. Circulation 100, 48-54 (1999).
47. Swartbol, P., Truedsson, L. & Norgren, L. Adverse reactions during endovascular treatment of aortic aneurysms may be triggered by interleukin 6 release from the thrombotic content. J. Vasc. Surg. 28, 664-668 (1998).
48. Jones, K. G. et al. interleukin-6 (iL-6) and the prognosis of abdominal aortic aneurysms. Circulation 103, 2260-2265 (2001).
49. Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P. & Hennekens, C. H. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 97, 425-428 (1998).
50. Powell, J. T., Muller, B. R. & Greenhalgh, R. M. Acute phase proteins in patients with abdominal aortic aneurysms. J. Cardiovasc. Surg. (Torino) 28, 528-530 (1987).
51. Ridker, P. M. et al. C-reactive protein levels and outcomes after statin therapy. N. Engl. J. Med. 352, 20-28 (2005).
52. Vainas, T. et al. Serum C-reactive protein level is associated with abdominal aortic aneurysm size and may be produced by aneurysmal tissue. Circulation 107, 1103-1105 (2003).
53. Wanhainen, A. et al. Risk factors associated with abdominal aortic aneurysm: a population-based study with historical and current data. J. Vasc. Surg. 41, 390-396 (2005).
54. Domanovits, H. et al. Acute phase reactants in patients with abdominal aortic aneurysm. Atherosclerosis 163, 297-302 (2002).
55. Wood, W. G. et al. Evaluation of a sensitive immunoluminometric assay for the determination of C-reactive protein (CRP) in serum and plasma and the establishment of reference ranges for different groups of subjects. Clin. Lab. 46, 131-140 (2000).
56. Norman, P., Spencer, C. A., LawrenceBrown, M. M. & Jamrozik, K. C-reactive protein levels and the expansion of screen-detected abdominal aortic aneurysms in men. Circulation 110, 862-866 (2004).
57. Lindholt, J. S., Erlandsen, E. J. & Henneberg, E. W. Cystatin C deficiency is associated with the progression of small abdominal aortic aneurysms. Br. J. Surg. 88, 1472-1475 (2001).
58. Vega de Ceniga, M. et al. Search for serum biomarkers associated with abdominal aortic aneurysm growth-a pilot study. Eur. J. Vasc. Endovasc. Surg. 37, 297-299 (2009).
59. Benowitz, N. L. Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction. Clin. Pharmacol. Ther. 83, 531-541 (2008).
60. Brady, A. R., Thompson, S. G., Fowkes, F. G., Greenhalgh, R. M. & Powell, J. T. Abdominal aortic aneurysm expansion: risk factors and time intervals for surveillance. Circulation 110, 16-21 (2004).
61. Buckley, C. et al. Accelerated enlargement of experimental abdominal aortic aneurysms in a mouse model of chronic cigarette smoke exposure. J. Am. Coll. Surg. 199, 896-903 (2004).
62. Franks, P. J., Edwards, R. J., Greenhalgh, R. M. & Powell, J. T. Risk factors for abdominal aortic aneurysms in smokers. Eur. J. Vasc. Endovasc. Surg. 11, 487-492 (1996).
63. Cannon, D. J., Casteel, L. & Read, R. C. Abdominal aortic aneurysm, Leriche’s syndrome, inguinal herniation, and smoking. Arch. Surg. 119, 387-389 (1984).
64. Kimura, S., Nishinaga, M., Ozawa, T. & Shimada, K. Thrombin generation as an acute effect of cigarette smoking. Am. Heart J. 128, 7-11 (1994).
65. Schneiderman, J. et al. Expression of fibrinolytic genes in atherosclerotic abdominal aortic aneurysm wall. A possible mechanism for aneurysm expansion. J. Clin. Invest. 96, 639-645 (1995).
66. MacSweeney, S. T., Ellis, M., Worrell, P. C., Greenhalgh, R. M. & Powell, J. T. Smoking and growth rate of small abdominal aortic aneurysms. Lancet 344, 651-652 (1994).
67. Russell, R. E. et al. Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am. J. Respir. Cell. Mol. Biol. 26, 602-609 (2002).
68. Nordskog, B. K., Fields, W. R., Hellmann, G. M. Kinetic analysis of cytokine response to cigarette smoke condensate by human endothelial and monocytic cells. Toxicology 212, 87-97 (2005).
69. Byron, K. A., Varigos, G. A. & Wootton, A. M. iL-4 production is increased in cigarette smokers. Clin. Exp. Immunol. 95, 333-336 (1994).
70. Wilmink, T. B., Quick, C. R. & Day, N. E. The association between cigarette smoking and abdominal aortic aneurysms. J. Vasc. Surg. 30, 1099-1105 (1999).
71. Boushey, C. J., Beresford, S. A., Omenn, G. S. & Motulsk, A. G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 274, 1049-1057 (1995).
72. Brunelli, T. et al. High prevalence of mild hyperhomocysteinemia in patients with abdominal aortic aneurysm. J. Vasc. Surg. 32, 531-536 (2000).
73. Warsi, A. A., Davies, B., Morris-Stiff, G., Hullin, D. & Lewis, M. H. Abdominal aortic aneurysm and its correlation to plasma homocysteine and vitamins. Eur. J. Vasc. Endovasc. Surg. 27, 75-79 (2004).
74. Spark, J. I., Laws, P & Fitridge, R. The incidence of hyperhomocysteinaemia in vascular patients. Eur. J. Vasc. Endovasc. Surg. 26, 558-561 (2003).
75. Strauss, E., Waliszewski, K., Gabriel, M., Zapalski, S. & Pawlak, A. L. increased risk of the abdominal aortic aneurysm in carriers of the MTHFR 677T allele. J. Appl. Genet. 44, 85-93 (2003).
76. Bescond, A. et al. influence of homocysteine on matrix metalloproteinase-2: activation and activity. Biochem. Biophys. Res. Commun. 263, 498-503 (1999).
77. Sofi, F. et al. High levels of homocysteine, lipoprotein(a) and plasminogen activator inhibitor-1 are present in patients with abdominal aortic aneurysm. Thromb. Haemost. 94, 1094-1098 (2005).
78. Lindholt, J. S., Möller, J., Henneberg, E. W. & Scient, C. Mild hyperhomocysteinemia is associated with impaired renal function but not with progression of small abdominal aortic aneurysms. Int. J. Angiol. 11, 95-98 (2002).
79. Halazun, K. J. et al. Hyperhomocysteinaemia is associated with the rate of abdominal aortic aneurysm expansion. Eur. J. Vasc. Endovasc. Surg. 33, 391-396 (2007).
80. O’Regan, A. & Fleming, C. Osteopontin as a biomarker for ovarian cancer. JAMA 287, 3208-3210 (2002).
81. Wang, K. X. & Denhardt, D. T. Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev. 19, 333-345 (2008).
82. Golledge, J. et al. Association between osteopontin and human abdominal aortic aneurysm. Arterioscler. Thromb. Vasc. Biol. 27, 655-660 (2007).
83. Golledge, J., McCann, M., Mangan, S., Lam, A. & Karan, M. Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke 35, 1636-1641 (2004).
84. Lai, C. F. et al. An osteopontin-NADPH oxidase signaling cascade promotes pro-matrix metalloproteinase 9 activation in aortic mesenchymal cells. Circ. Res. 98, 1479-1489 (2006).
85. Seipelt, R. G. et al. Osteopontin expression and adventitial angiogenesis induced by local vascular endothelial growth factor 165 reduces experimental aortic calcification. J. Thorac. Cardiovasc. Surg. 129, 773-781 (2005).
86. Urbonavicius, S. et al. Proteomic identification of differentially expressed proteins in aortic wall of patients with ruptured and nonruptured abdominal aortic aneurysms. J. Vasc. Surg. 49, 455-463 (2009).